Casey Sharp, NP
Family · Danville, VANPI 1063961472
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $54,175 of the $62,814 with a category attached, or 86.2%. AbbVie accounts for 90.8% of it on its own, with 36 other manufacturers making up the rest. 2025 is the largest year on record at $26,743, more than ten times the $2,072 reported in 2021. Among family clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 622 payments — averaging $100.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$57K
- Otsuka America Pharmaceutical, Inc.$836
- Neurocrine Biosciences, Inc.$667
- Alkermes, Inc.$466
- Lundbeck LLC$419
- Supernus Pharmaceuticals, Inc.$388
- plus $3K from 31 others
What the payments were for
- Speaking & faculty fees$54,17586%
- Travel & lodging$2190%
- Food & beverage$8,36313%
- Education$570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 283 | $57,044 |
| Otsuka America Pharmaceutical, Inc. | 55 | $836 |
| Neurocrine Biosciences, Inc. | 31 | $667 |
| Alkermes, Inc. | 24 | $466 |
| Lundbeck LLC | 26 | $419 |
| Supernus Pharmaceuticals, Inc. | 22 | $388 |
| Novo Nordisk | 24 | $358 |
| Abbott | 23 | $333 |
| Corium, LLC | 15 | $270 |
| Lilly USA, LLC | 13 | $228 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $206 |
| Axsome Therapeutics, Inc. | 9 | $178 |
| Amgen | 8 | $168 |
| Teva Pharmaceuticals USA, Inc. | 9 | $168 |
| Biohaven Pharmaceuticals, Inc. | 5 | $109 |
| Noven Therapeutics, LLC | 6 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $99 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $91 |
| Amarin Pharma, Inc. | 6 | $85 |
| Vanda Pharmaceuticals Inc. | 3 | $74 |
| Haemonetics Corporation | 1 | $67 |
| Pfizer | 3 | $50 |
| GSK | 3 | $49 |
| Astellas Pharma US Inc | 3 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Phathom Pharmaceuticals, Inc. | 2 | $43 |
| Sunovion Pharmaceuticals Inc. | 3 | $29 |
| AstraZeneca | 2 | $28 |
| Eisai Inc. | 2 | $26 |
| Bardy Diagnostics, Inc. | 1 | $25 |
| Novartis | 1 | $21 |
| Almatica Pharma LLC | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$62,814 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 19 | $150,976 |
| VraylarCariprazine Hcl | 112 | $148,805 |
| RexultiBrexpiprazole | 80 | $113,822 |
| OzempicSemaglutide | 44 | $41,800 |
| MounjaroTirzepatide | 39 | $40,538 |
| RybelsusSemaglutide | 13 | $23,365 |
| NuedextaDextromethorphan Hbr/Quinidine | 17 | $22,759 |
| VascepaIcosapent Ethyl | 37 | $15,791 |
| MyrbetriqMirabegron | 13 | $5,746 |
| Lurasidone Hcl | 19 | $4,382 |
| Vilazodone Hcl | 58 | $3,299 |
| Duloxetine Hcl | 137 | $2,425 |
| Clozapine | 44 | $2,165 |
| Lamotrigine | 196 | $2,107 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 45 | $2,065 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $667 | $150,97619 claims |
| AbbVieVraylar | $57,044 | $148,805112 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $836 | $113,82280 claims |
| Novo NordiskOzempic, Rybelsus | $358 | $65,16557 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $228 | $41,351100 claims |
| Astellas Pharma US IncMyrbetriq | $49 | $5,74613 claims |
| Almatica Pharma LLCSertraline Hcl | $18 | $852120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Danville
- Nancy FolleyDanville$37K
- Phyllis ScarceDanville$18K
- Edythe BoitnottDanville$11K
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.